Genre
- Journal Article
G28-5 sFv-PE40 is a single-chain immunotoxin targeted to CD40, which is highly expressed on human hematologic malignancies, including non-Hodgkin's lymphoma, B-lineage leukemias, multiple myeloma, and Hodgkin's disease, as well as certain carcinomas. In vitro analysis showed that this monovalent immunotoxin had a binding affinity of 3 nmol/L, within 15-fold of the bivalent parental monoclonal antibody. G28-5 sFv-PE40 was stable when incubated in mouse serum at 37 degrees C for 6 hours and cleared from the circulation of mice with a half-life of 16.7 minutes. This immunotoxin was effective in treating human Burkitt's lymphoma xenografted SCID mice with complete responses, defined by an asymptomatic phenotype for greater than 120 days, obtained at doses of 0.13 to 0.26 mg/kg. The efficacy of treatment was dependent on the schedule used, with every three days for five injections being the most effective tested. The toxicity of G28-5 sFv-PE40 was examined in SCID mice, rats, and monkeys, with the maximum tolerated dose being 0.48, 1.0, and 1.67 mg/kg, respectively. Comparative immunohistology showed that the G28-5 specificity was qualitatively similar between human and monkey tissue. In summary, G28-5 sFv-PE40 was effective at inducing complete antitumor responses in lymphoma xenografted mice at doses that were well tolerated in mice, rats, and monkeys. (C) 1997 by The American Society of Hematology.
BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL IMMUNOL,SEATTLE,WA 98121. BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT AUTOIMMUN TRANSPLANTAT,SEATTLE,WA 98121. BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT DRUG SAFETY EVALUAT,SYRACUSE,NY.
PHILADELPHIA; INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399
W B SAUNDERS CO
PT: J; CR: ALDERSON MR, 1993, J EXP MED, V178, P669 BRASLAWSKY GR, 1990, CANCER RES, V50, P6008 BRINKMANN U, 1994, BBA-REV CANCER, V1198, P27 CAUX C, 1994, J EXP MED, V180, P1263 CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766 CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494 CLARK EA, 1987, EUR J IMMUNOL, V171, P1799 DEVESA SS, 1992, CANCER RES, V52, S5432 FRANCISCO JA, 1995, CANCER RES, V55, P3099 FRANCISCO JA, 1996, J IMMUNOL, V157, P1652 FREEDMAN AS, 1994, HARRISONS PRINCIPLES, P1774 FRIEDMAN PN, 1993, J IMMUNOL, V150, P3054 GALY AHM, 1992, J IMMUNOL, V149, P775 GHETIE MA, 1990, INT J CANCER, V45, P481 GROSSBARD ML, 1993, BLOOD, V81, P2263 GROSSBARD ML, 1993, IMMUNOTOXIN THERAPY, V68, P111 HOLLENBAUGH D, 1995, J EXP MED, V182, P33 HUANG YW, 1993, CANCER RES, V53, P1392 JOHNSSON B, 1991, ANAL BIOCHEM, V145, P229 KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342 KAWATA A, 1994, CANCER RES, V54, P2688 KIENER PA, 1995, J IMMUNOL, V155, P4917 LING NR, 1987, LEUCOCYTE TYPING, V3, P302 NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550 OGRADY JT, 1994, AM J PATHOL, V144, P21 PALACKDHARRY CS, 1994, ONCOLOGY, V8, P67 PASQUALUCCI L, 1995, HAEMATOLOGICA, V80, P546 PAULIE S, 1985, CANCER IMMUNOL IMMUN, V20, P23 PEARCE N, 1992, CANCER RES, V52, P5496 PELLATDECEUNYNCK C, 1994, BLOOD, V84, P2597 PRESS OW, 1993, MALIGNANT LYMPHOMAS, P127 REITER Y, 1994, J BIOL CHEM, V269, P18327 SIEGALL CB, 1994, P NATL ACAD SCI USA, V91, P9514 UCKUN FM, 1990, BLOOD, V76, P2449 VITETTA ES, 1991, CANCER RES, V51, P4052 YELLIN MJ, 1995, J LEUKOCYTE BIOL, V58, P209; NR: 36; TC: 18; J9: BLOOD; PG: 8; GA: XE974
Source type: Electronic(1)
Language
- English
Subjects
- ACTIVATION
- ANTITUMOR-ACTIVITY
- Cytokines
- hematology
- therapy
- DISEASE
- ANTIGEN
- lymphoma
- B-CELLS
- EXPRESSION
- HUMAN MONOCYTES